• Kidney Research and Clinical Practice
• /
• 제36권3호
• /
• pp.257-263
• /
• 2017

Background Rituximab (RTX) can be used as a rescue therapy for steroid-dependent nephrotic syndrome (SDNS). However, the efficacy and safety of long-term, repeated use of RTX are not established. This study was conducted to assess the efficacy and safety of long-term, repeated RTX treatment in children. Methods Eighteen consecutive child patients with SDNS who were treated with three or more cycles of RTX for one year or longer were recruited, and their medical records were retrospectively reviewed. Results The patients were followed for $4.7{\pm}1.9years$ and received $5.2{\pm}2.3cycles$ of RTX over $2.8{\pm}1.1years$. Approximately 70% of the additional RTX cycles were administered due to recovery of B-cells without relapse. The relapse rate decreased from $3.4{\pm}2.0per$ year initially to $0.4{\pm}0.8per$ year at the third year after RTX treatment. Approximately 10% of the RTX infusions were accompanied by mild infusion reactions. Eight patients showed sustained remission without any oral medication after the last cycle of RTX, while 10 patients had one or more episodes of relapse after the last cycle of RTX. The relapse rate in the latter group decreased from $2.8{\pm}1.5per$ year before RTX treatment to $1.3{\pm}0.8per$ year after cessation of RTX treatment. No significant differences in clinical parameters were found between the two groups. Conclusion This retrospective study showed that pre-emptive and long-term, repeated RTX treatment is relatively effective and safe in children with SDNS. However, well-designed prospective studies are needed to confirm these findings.

• Childhood Kidney Diseases
• /
• 제22권1호
• /
• pp.1-6
• /
• 2018

Rituximab (RTX) is a chimeric monoclonal antibody that inhibits CD20-mediated B-cell proliferation and differentiation. Several studies have examined its use in intractable nephrotic syndrome (NS) with some positive results. However, those studies examined such effects for a short-term period of 1 year, and some patients continued to relapse after a lapse in RTX treatment. Our use of RTX as a maintenance therapy (RTX injection when the CD19 cell count exceeded $100-200/{\mu}L$ before relapse) showed some noticeable efficacy. We used RTX in 19 patients with steroid-dependent NS (SDNS). In 12 patients treated with RTX maintenance therapy, only one relapse occurred. The mean treatment period was $23.4{\pm}12.7months$, and the mean number of RTX administrations was $3.9{\pm}1.6$. The relapse rates were decreased (from 2.68/year to 0.04/year), and the drug-free period also increased (from 22.5 days/year to 357.1 days/year) during maintenance therapy. The other seven patients were treated with one cycle of RTX or additional cycles in case of relapse (non-maintenance therapy). Relapse rates were significantly decreased after RTX treatment (from 1.76/year to 0.96/year, P=0.017). The relapse-free period was $15.55{\pm}7.38$ (range, 5.3-30.7) months. No severe side effects of RTX were found except for a hypersensitivity reaction such as fever and chills during its infusion. In conclusion, RTX is considered an effective and safe option to reduce the relapse rate by a single- or maintenance-interval therapy in SDNS.

• Journal of Microbiology
• /
• 제45권2호
• /
• pp.146-152
• /
• 2007

A mutant exhibiting decreased cytotoxic activity toward INT-407 intestinal epithelial cells and carrying a mutation in the rtx gene cluster that consists of rtxCA and rtxBDE operons was screened from a library of V. vulnificus mutants. The functions of the rtxA gene, assessed by constructing an isogenic mutant and evaluating its phenotypic changes, demonstrated that RtxA is essential for the virulence of V. vulnificus in mice as well as in tissue cultures.

• Childhood Kidney Diseases
• /
• 제10권2호
• /
• pp.219-227
• /
• 2006

Purpose : We aim to identify the clinical and demographic characteristics in children who underwent renal transplantation(RTx) and to evaluate the influence on growth of RTx in children. Methods : We reviewed 17 medical records of chronic renal failure patients who underwent RTx from April 1992 and June 2004 at Busan Paik Hospital. Age and sex distribution, cause of disease, donor analysis, patient and graft survival rate, and the status of growth after RTx were analysed by retrospective study. Results : Eighteen RTx were performed in 17 patients(8 boys, 9 girls). The mean age at the time of RTx was $15.8{\pm}3.5$ years and the mean duration of dialysis therapy before RTx was $22.4{\pm}18.0$ months. The 1 year and 5 year patient survival rate were each 100%, and the 1 year and 5 year graft survival rate were 88%, 36% respectively. The most common cause of graft failure was chronic rejection. The mean final height of male patients was $162.8{\pm}10.0$ cm(143.0-172.5 cm) and of female patients was $154.5{\pm}12.1$ cm(135.8-160.0 cm). The mean height standard deviation score(Ht SDS) increased after RTx from -1.95 to -1.53 but the increment rate was not statistically significant. Similar changes were noted in individual patient analysis. Also there was no significant difference between the living-related donors and cadaveric donors. Conclusion : Our data shows that even successful RTx rarely results in full growth rehabilitation. To overcome retarded growth in children with chronic renal failure, appropriate combined management of metabolic and nutritional problems, correction of anemia, proper use of recombinant growth hormone therapy, early renal transplantation and shortening of the duration of dialysis would be necessary.

• IMMUNE NETWORK
• /
• 제16권4호
• /
• pp.233-241
• /
• 2016

DCs, like the sensory neurons, express vanilloid receptor 1 (VR1). Here we demonstrate that the VR1 agonists, capsaicin (CP) and resiniferatoxin (RTX), enhance antiviral CTL responses by increasing MHC class I-restricted viral antigen presentation in dendritic cells (DCs). Bone marrow-derived DCs (BM-DCs) were infected with a recombinant vaccinia virus (VV) expressing OVA (VV-OVA), and then treated with CP or RTX. Both CP and RTX increased MHC class I-restricted presentation of virus-encoded endogenous OVA in BM-DCs. Oral administration of CP or RTX significantly increased MHC class I-restricted OVA presentation by splenic and lymph node DCs in VV-OVA-infected mice, as assessed by directly measuring OVA peptide SIINFEKL-K^b complexes on the cell surface and by performing functional assays using OVA-specific CD8 T cells. Accordingly, oral administration of CP or RTX elicited potent OVA-specific CTL activity in VV-OVA-infected mice. The results from this study demonstrate that VR1 agonists enhance anti-viral CTL responses, as well as a neuro-immune connection in anti-viral immune responses.

• 한국군사과학기술학회지
• /
• 제14권3호
• /
• pp.353-358
• /
• 2011

In this paper, we have introduced a Missile In the Loop Simulation(MILS) Software developed for the missile ground test, which is based on a commercial hard real-time operating system(OS) on Windows platform called as Real-Time eXtension(RTX). MILS software makes it possible to test overall system functions of a integrated missile on the ground in the flight conditions by real-time imitating its inertial data. By means of MILS, we have performed missiles ground tests, which result in successful real flight tests.

• The Korean Journal of Physiology and Pharmacology
• /
• 제20권1호
• /
• pp.129-136
• /
• 2016

This study was performed to investigate whether an intra-articular injection of transient receptor potential vanilloid 1 (TRPV1) receptor agonist, resiniferatoxin (RTX) would alleviate behavioral signs of arthritic pain in a rat model of osteoarthritis (OA). We also sought to determine the effect of RTX treatment on calcitonin gene-related peptide (CGRP) expression in the spinal cord. Knee joint inflammation was induced by intra-articular injection of monosodium iodoacetate (MIA, $8mg/50{\mu}l$) and weight bearing percentage on right and left hindpaws during walking, paw withdrawal threshold to mechanical stimulation, and paw withdrawal latency to heat were measured to evaluate pain behavior. Intra-articular administration of RTX (0.03, 0.003 and 0.0003%) at 2 weeks after the induction of knee joint inflammation significantly improved reduction of weight bearing on the ipsilateral hindlimb and increased paw withdrawal sensitivity to mechanical and heat stimuli. The reduction of pain behavior persisted for 3~10 days according to each behavioral test. The MIA-induced increase in CGRP immunoreactivity in the spinal cord was decreased by RTX treatment in a dose-dependent manner. The present study demonstrated that a single intra-articular administration of RTX reduced pain behaviors for a relatively long time in an experimental model of OA and could normalize OA-associated changes in peptide expression in the spinal cord.

• Childhood Kidney Diseases
• /
• 제19권2호
• /
• pp.176-179
• /
• 2015

Rituximab (RTX), a monoclonal antibody against the B-cell marker CD20, is commonly used as a treatment for antibody-mediated diseases or B-lymphocyte-mediated diseases. Destruction of B cells may reverse the disease course in many conditions; however, patients who are treated with RTX cannot respond appropriately to de novo infection due to lack of B lymphocytes. Here, we report one such case. A 7-year-old renal allograft recipient presented with severe anemia due to parvovirus infection after RTX treatment. The patient had focal segmental glomerulosclerosis and had received cadaveric kidney transplantation 6 months previously. She was treated with high-dose steroid for acute rejection and RTX for Epstein Barr Virus infection 3 months previously. At presentation, her hemoglobin level was 5.4 g/dL and leukocyte and platelet counts were normal. She had microcytic normochromic anemia and high viral load of parvovirus B19(70,578 copies/mL). Intravenous immunoglobulin ($200mg/kg{\cdot}d$) treatment controlled the progression of anemia and parvovirus infection. De novo parvovirus infection during the B lymphocyte-depletion period may have precipitated the severe anemia in this case. Close monitoring of infection is required after RTX therapy.

• 정보처리학회논문지:컴퓨터 및 통신 시스템
• /
• 제12권2호
• /
• pp.69-76
• /
• 2023

매년 수십만 개의 암호를 분실하거나 잊어버리면서 합법적인 소유자나 권한을 부여받은 법 집행 담당자가 필요한 정보를 사용할 수 없게 된다. 이러한 암호를 되찾기 위해 암호 해독(Password Cracking)이 사용된다. 암호 해독에 CPU 대신 GPU를 사용하면 복구 과정에서 필요한 많은 양의 계산을 신속하게 처리할 수 있다. 본 논문은 현재 가장 많이 사용되는 PDF 1.4 -1.6 버전의 암호 해독에 중점을 두고 CUDA를 사용하여 GPU에서 최적화한다. MD5 알고리즘의 불필요 연산 제거, RC4 알고리즘의 32비트 워드 통합 구현, 공유메모리 사용의 기법을 사용하였다. 또한 성능향상에 영향을 미치는 블록, 스레드 수 탐색을 위해 오토튠 기법을 사용하였다. 결과적으로 RTX 3060, RTX 3090 환경에서 블록 크기 65,536, 스레드 크기 96에서 31,460 kp/s(kilo passwords per second), 66,351 kp/s의 처리량을 보였으며, 기존 최고 처리량을 보여주는 해시캣의 처리량보다 각각 22.5%, 15.2%를 향상시켰다.

• 수산해양기술연구
• /
• 제38권3호
• /
• pp.249-255
• /
• 2002

소형 레이더 신호를 정량적으로 분석하여 해상물표의 운동정보를 실시간으로 추출 및 표시하기 위한 radar target extractor(RTX)를 개발하고, 이 장치를 소형 레이더 장치에 부착시켜 소형 연근해 어선에서도 타선의 진운동정보나 충돌회피정보와 같은 각종의 항해정보를 활용토록 하기 위한 연구를 수행하였다. 본 연구에서 개발한 RTX는 IBM PC 의 ISA bus를 통해 데이터를 입출력할 수 있도록 설계된 신호처리장치로서, 일반 선박용 레이더에서 출력되는 video signal, trigger, antenna bearing pulse, antenna heading mark를 직접 입력할 수 있도록 하였다. 이 장치는 레이더 펄스신호가 해상에 존재하는 물표로부터 반사되어 수신될 때, 그 물표의 신호정보 및 위치좌표정보를 PC 의 CPU 에 의해 처리하지 않고 RTX 자체에 내장된 전용 DSP를 이용하여 실시간으로 처리하도록 하였다. 이 장치에 서 video 신호는 analog devices 사의 AD9042 (12 bit, 40 MHZ monolithic A/D converter)를 이용하여 digital 신호로 변환되고, 그 화상 신호는 CRT에 PPI 방식으로 표시되었다. 이 때 안테나가 회전하면서 탐지한 레이더 물표의 echo 신호는 echo 신호의 강도가 증가하면서 다른 물표의 위치와 구별되면 하나의 물표로서 판정한다. 이 경우, 표적식별 알고리즘은 물표가 미리 설정한 물표포착영역(target acquiring zone)내에 있고, 해당 물표의 크기와 다른 물표와의 거리등에 대한 데이터가 식별기준을 만족하는가에 대한 처리를 수행하도록 개발되었다. 본 연구는 현재 소형어선에 탑재되고 있는 소형레이더의 성능 향상에 크게 기여할 것으로 판단되고, 또한 소형어선용 저가형 ARPA 시스템의 국산화에 필요한 기반기술을 제공할 수 있을 것으로 판단된다.